References
- Rajendran PM, Young D, Maurer T et al. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrob. Agents Chemother.51, 4044–4048 (2007).
- Stevens DL, Bisno AL, Chambers HF et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin. Infect. Dis.41, 1373–1406 (2005).
- Llera JL, Levy RC. Treatment of cutaneous abscess: a double-blind clinical study. Ann. Emerg. Med.14, 15–19 (1985).
- Moran GJ, Krishnadasn A, Gorwitz RJ et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med.355, 666–674 (2006).
- Fridkin SK, Hageman JC, Morrison M et al. Methicillin-resistant Staphylococcus aureus in three communities. N. Engl. J. Med.352, 1436–1444 (2005).
- Daum RS. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N. Engl. J. Med.357, 380–390 (2007).
- Francis JS, Doherty MC, Lopatin U et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton–Valentine leukocidin gene. Clin. Infect. Dis.40, 100–107 (2005).
- Adem PV, Montgomery CP, Husain AN et al.Staphylococcus aureus sepsis and the Waterhouse–Friderichsen syndrome in children. N. Engl. J. Med.353, 1245–1251 (2005).
- Miller LG, Perdreau-Remington F, Rieg G et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N. Engl. J. Med.352, 1445–1453 (2005).
- Kaplan SL, Hulten KG, Gonzalez BE et al. Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin. Infect. Dis.40, 1785–1791 (2005).
- Ellis MW, Griffith ME, Dooley DP et al. Targeted intranasal mupirocin to prevent colonization and infection by community-associated methicillin-resistant Staphylococcus aureus strains soldiers: a cluster randomized controlled trial. Antimicrob. Agents Chemother.51, 3591–3598 (2007).
- Lee MC, Rios AM, Aten MF et al. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus.Pediatr. Infect. Dis. J.23, 123–127 (2004).
- Ruhe JJ, Smith N, Bradsher RW, Menon A. Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infection: impact of antimicrobial therapy on outcome. Clin. Infect. Dis.44, 777–784 (2007).
- Harris HW, Young DM. Care of injection drug users with soft tissue infections in San Francisco, California. Arch. Surg.137, 1217–1222 (2002).
- Young DM, Harris HW, Charlebois ED et al. An epidemic of methicillin-resistant Staphylococcus soft tissue infection among medically underserved patients. Arch. Surg.139, 947–953 (2004).
- Weigelt J, Itani K, Stevens D et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother.49, 2260–2266 (2005).
- Jauregui LE, Babazadeh S, Seltzer E et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin. Infect. Dis.41, 1407–1415 (2005).
- Macfie J, Harvey J. The treatment of acute superficial abscesses: a prospective clinical trial. Br. J. Surg.64, 264–266 (1977).
- Paydar KZ, Hansen SL, Charlebois ED, Harris HW, Young DM. Inappropriate antibiotic use in soft tissue infections. Arch. Surg.141, 850–856 (2006).
- Stevens DL, Ma Y, Salmi DB, McIndoo E, Wallace RJ, Bryant AE. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus. J. Infect. Dis.195, 202–211 (2007).
Website
- Gorwitz RJ, Jernigan DB, Jernigan JA, Powers JH; and Participants in the CDC-convened experts’ meeting on management of MRSA in the community. Strategies for clinical management of MRSA in the community: summary of an expert’s meeting Convened by the Centers for Disease Control and Prevention. March 2006 www.cdc.gov/ncidod/dhqpr/ar_mrsa_ ca.html.